Benny Biochemical Pharmaceutical Co., Ltd. is located in Changzhou, Changzhou National Hi-Tech Development Zone, is a national high-tech enterprise, Jiangsu Province, technology-intensive knowledge-intensive enterprises, the state, "the new students with high enzyme technology products industrialization demonstration project "and state the" three drug base "of key enterprises.

The total investment of 120 million yuan, covers an area of 73,260 square meters, construction area of 20,000 square meters, integrated production workshop, administrative center, research and development center, quality security center and other accessories. The entire plant system according to GMP standard design, construction, green area accounts for 60%of the total area of the plant.

< P style = "TEXT-INDENT: 2em"> main production freeze-dried powder (containing antineoplastic agents), small volume injection, tablets, capsules, bulk drugs. Representative products of pancreatic kallikrein, pancreatic elastase, L-asparaginase, heparin and so on. All products have passed the GMP authentication.

"Talent is the technology is root, innovation is the soul." For two decades, the company take the path of research cooperation has developed pancreatic kallikrein, elastase, L-asparaginase, digestive enzymes and a variety of advanced compound to fill the gaps in the enzyme preparation products. Especially the first time in the world of pancreatic kallikrein for the prevention of diabetes complications, and success, thus laying a basis of competition in this field. To strengthen the scientific research, companies and pharmaceutical China Pharmaceutical University College JV to build a "bio-pharmaceutical engineering and technology center in Changzhou", dedicated to natural medicine, synthetic drugs, genetic engineering drugs and other categories of drug research and development, is currently being developed with independent intellectual property rights and anti-drug chemotherapy in the treatment of cataract Shengbai new drugs, in the pharmacological and clinical research has made great progress. Such as a joint venture with Nanjing University School of Medicine to build the human stem cell engineering institute, is the production and marketing of human stem cell products into the high-tech fields. Stick to brand products, play a brand of the road. Over the years, relying on technological progress, constantly improving product technology content and quality and varieties of heparin is the first in COS-site certification by the European Union and drug test for the virus. Key species, "Yee open" internal quality standards by the State Pharmacopoeia Commission upgraded to national pharmacopoeia standards, at home and abroad with high visibility.

< P style = "TEXT-INDENT: 2em"> "to open up is a fan, the size of the boat." In recent years, the company has been operating on the scale of implementation, first-class products, business strategy, efforts to develop domestic and international market, sales network throughout the country 29 provinces (cities), districts, and Germany, Italy, the United States, Japan, Korea, India, Brazil and other countries. The market scale for rapid economic development in recent years, rising strength of the company, effective in mid-growth, product sales, profits are increasing continuously faster rate.

Looking ahead, the company will be the medical and biochemical enzymes and polysaccharide drugs such as features, and vigorously expand domestic and foreign chemical and biological drug market; to create a harmonious cultural environment to attract more of insight to the company create a better future; market-oriented and develop more "safer, more effective, more economical," the biochemical medicines; with global customers and partners to maintain and build long-term stable and mutually beneficial strategic partnership.